Overexpression of FASN, in fact, is a predictor of recurrence in stage I breast carcinoma [41], lung carcinoma [42], endometrial carcinoma [43] patients and correlate with a worst prognosis in breast carcinoma [44] and ovarian carcinoma [45] patients. Here, FASN is linked to breast carcinoma.